How long does stem cell therapy for Macular Degeneration & Vision last?
The timing and durability of any visual benefit and long-term graft survival remain uncertain. Animal findings cannot establish human durability, and immune, proliferative, surgical and retinal risks require extended follow-up. Providers should not promise a response window or lasting vision improvement for an unapproved product.
How stem cells are studied for Macular Degeneration & Vision
Age-related macular degeneration (AMD) and inherited retinal diseases can damage photoreceptors or the retinal pigment epithelium (RPE), but they are distinct conditions with different causes and established management. Investigational cell approaches include RPE or retinal progenitor products derived from sources such as induced pluripotent stem cells (iPSC). Laboratory differentiation or integration hypotheses do not establish restored vision in people. Product identity, surgical route, immune risk and disease stage are critical. The registry table on this page lists relevant studies and their current recruitment status.
Am I a candidate? → · Macular Degeneration & Vision: full overview → · Macular Degeneration & Vision cost → · Cost →
Evidence checked against ISSCR, FDA and EMA guidance. See our editorial standards. This is information, not medical advice. Educational information, not medical advice; figures indicative.
Sources & further reading
More on this condition
- Macular Degeneration & Vision: cell-therapy evidence and registered trials
- How much does stem cell therapy for Macular Degeneration & Vision cost? (2026)
- Macular Degeneration & Vision stem cell therapy — your questions answered (2026)
- Macular Degeneration & Vision: cell-therapy evidence by therapy class